LeonaBio (LONA) 12th Annual Cantor Fitzgerald Global Healthcare Conference summary

Company overview and strategic focus

• Recently established, focused on developing lasofoxifene, a unique SERM for metastatic breast cancer.

• Raised $246 million and is led by experienced management and investors.

• Emphasizes collaboration and aims to become the partner of choice in second-line metastatic breast cancer.

Lasofoxifene development and differentiation

• Lasofoxifene is a potent SERM, showing superior activity against ESR1-mutated breast cancer compared to SERDs.

• Demonstrates high affinity for mutated estrogen receptors, inactivating them without degrading healthy receptors.

• Offers quality-of-life benefits by avoiding antagonism of estrogen receptors in non-breast tissues.

Clinical trial landscape and ELAINE program

• ELAINE-1 and ELAINE-2 trials showed promising efficacy and safety, with no significant thrombotic events.

• ELAINE-3 is a 600-patient, fully enriched ESR1 mutation trial comparing lasofoxifene-abemaciclib to fulvestrant-abemaciclib.

• The trial is powered to detect a clinically meaningful PFS difference, aiming for double-digit months.